Drug intelligence / Profile preview

ASM-002

Development stage: Preclinical
Lead developer: Odan Laboratories
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

ASM-002 is a small molecule nicotinic acetylcholine receptor (nAChR) agonist originally developed by Asmacure Ltée (later acquired by Odan Laboratories) for the treatment of inflammatory and respiratory diseases, such as asthma. Derived from the structural modification of dimethylphenylpiperazinium (DMPP), ASM-002 exhibits anti-inflammatory and smooth muscle-relaxing properties. In preclinical studies, including mouse and dog models of asthma, ASM-002 demonstrated dose-dependent relaxation of tracheal smooth muscle and inhibition of cellular lung inflammation with efficacy comparable to prednisone.

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on ASM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASM-002.